Compare Stocks → the most reliable asset on earth is making a comeback (From DTI) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CLLSNASDAQ:INMBNASDAQ:JNCENASDAQ:TALS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLLSCellectis$2.67+3.9%$2.74$0.96▼$3.77$148.40M3.1342,579 shs7,361 shsINMBINmune Bio$11.63-2.1%$12.12$5.87▼$14.74$214.10M1.9978,448 shs92,870 shsJNCEJounce Therapeutics$1.88-2.6%$1.89$0.58▼$5.87$98.94M0.752.46 million shs11.60 million shsTALSTalaris Therapeutics$22.90-3.9%$18.84$0.89▼$27.95$979.30M2.18386,531 shs581,345 shsThe Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLLSCellectis+6.80%+8.98%-1.84%-21.24%+31.20%INMBINmune Bio-2.10%+0.35%-11.29%+1.57%+72.55%JNCEJounce Therapeutics0.00%0.00%0.00%0.00%+2.17%TALSTalaris Therapeutics-3.86%-48.74%-37.12%-19.25%+1,193.79%Trump’s “Tax Free” Retirement Strategy (Ad)Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLLSCellectis3.1322 of 5 stars3.53.00.00.03.82.50.6INMBINmune Bio0.8384 of 5 stars3.50.00.00.01.91.70.0JNCEJounce TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ATALSTalaris TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLLSCellectis3.00Buy$11.00311.99% UpsideINMBINmune Bio3.00Buy$16.0037.58% UpsideJNCEJounce TherapeuticsN/AN/AN/AN/ATALSTalaris Therapeutics2.00HoldN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLLSCellectis$25.73M5.77N/AN/A$2.76 per share0.97INMBINmune Bio$224K935.70N/AN/A$3.35 per share3.47JNCEJounce Therapeutics$82M1.21N/AN/A$3.54 per share0.53TALSTalaris TherapeuticsN/AN/AN/AN/A$4.33 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLLSCellectis-$106.14M-$1.67N/A∞N/A-346.65%-73.03%-32.22%N/AINMBINmune Bio-$27.30M-$1.52N/A∞N/A-12,246.88%-52.26%-38.08%3/28/2024 (Confirmed)JNCEJounce Therapeutics-$50.92M-$2.56N/AN/AN/AN/A-30.90%-26.31%N/ATALSTalaris Therapeutics-$73.89M-$1.79N/A∞N/AN/A-39.93%-37.37%N/ALatest CLLS, TALS, JNCE, and INMB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024N/AINMBINmune BioN/A-$0.44-$0.44N/AN/AN/A DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLLSCellectisN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/AJNCEJounce TherapeuticsN/AN/AN/AN/AN/ATALSTalaris TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLLSCellectis0.572.202.20INMBINmune Bio0.053.183.18JNCEJounce TherapeuticsN/A8.378.37TALSTalaris TherapeuticsN/A15.4115.41OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLLSCellectis63.90%INMBINmune Bio12.72%JNCEJounce Therapeutics80.66%TALSTalaris Therapeutics67.61%Insider OwnershipCompanyInsider OwnershipCLLSCellectis16.41%INMBINmune Bio36.10%JNCEJounce Therapeutics6.92%TALSTalaris Therapeutics16.50%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCLLSCellectis23155.58 million46.46 millionOptionableINMBINmune Bio1018.02 million11.52 millionOptionableJNCEJounce Therapeutics13752.63 million48.99 millionOptionableTALSTalaris Therapeutics8442.76 million35.71 millionNot OptionableCLLS, TALS, JNCE, and INMB HeadlinesSourceHeadlineLongitude Venture Partners III, L.P.'s Net Worthbenzinga.com - February 25 at 9:31 PMTalaris Therapeutics (TALS) Price Target Increased by 562.50% to 135.15msn.com - November 1 at 8:40 AMTalaris Thera (NASDAQ: TALS) stock to jump 1,000% then fall $15 - weird and complexdhakatribune.com - October 20 at 7:22 AMTalaris Therapeutics goes ex-dividend tomorrowmsn.com - October 19 at 3:47 PMTalaris Therapeutics, Inc.: Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Biofinanznachrichten.de - October 18 at 8:02 AMTalaris shareholders approve merger, 1-for-10 reverse stock splitmsn.com - October 17 at 10:28 PMTalaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Biofinance.yahoo.com - October 17 at 10:28 PMTalaris Therapeutics Inc [TALS] Insider Ildstad Suzanne sells 12,942 Shares – Insider Selling Alertknoxdaily.com - October 16 at 1:01 PMShares of Talaris Therapeutics Climb 5.2% on Special Dividend Tied to Mergermarketwatch.com - October 6 at 8:19 PMTalaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Biofinance.yahoo.com - October 6 at 8:19 PMNew York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris Therapeuticsfinance.yahoo.com - October 4 at 9:59 AMWe're Keeping An Eye On Talaris Therapeutics' (NASDAQ:TALS) Cash Burn Ratefinance.yahoo.com - September 12 at 5:34 PMSHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – TALS,bakersfield.com - August 23 at 11:00 PMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AEL, DEN, TALS, QUOTmarkets.businessinsider.com - August 15 at 6:25 PMImmunoFree Inc. has Acquired Talaris Therapeutics, Inc.'s Tolerance Businessfinance.yahoo.com - August 14 at 3:38 PMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NEX, TALS, QUOT, SURFmarkets.businessinsider.com - August 8 at 8:33 AMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TALS, NETI, AMED, GHLbakersfield.com - July 29 at 5:47 PMMoore Kuehn Encourages RETA, TALS, INPX, and DEN Investors to Contact Law Firmbenzinga.com - July 28 at 4:44 PMSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Talaris Therapeutics, Inc. (TALS)markets.businessinsider.com - July 27 at 11:10 AMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NETI, QUOT, TALS, CFMSmarkets.businessinsider.com - July 18 at 1:26 PMTalaris Therapeutics: Cashing Out Ahead Of Tourmaline Mergermsn.com - July 18 at 8:26 AMDirector Ildstad Suzanne sale 12,942 shares of Talaris Therapeutics Inc. [TALS]knoxdaily.com - July 14 at 11:38 PMTalaris Therapeutics (TALS) Price Target Increased by 66.67% to 12.75msn.com - July 6 at 8:45 PMNews: Talaris Therapeutics Inc.’s Director Ildstad Suzanne reduceds 12,942 sharesknoxdaily.com - July 3 at 6:19 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesHow to Invest in Artificial Intelligence in These Simple WaysMarch 7, 2024 1:08 PMView How to Invest in Artificial Intelligence in These Simple Ways5 Under-the-Radar Artificial Intelligence (AI) Stocks March 4, 2024 9:30 AMView 5 Under-the-Radar Artificial Intelligence (AI) Stocks Your Comprehensive Guide to Investing in Bank StocksMarch 1, 2024 10:41 AMView Your Comprehensive Guide to Investing in Bank Stocks3 Mining Stocks to Explode This Year on a Commodity Price SwingMarch 4, 2024 6:08 AMView 3 Mining Stocks to Explode This Year on a Commodity Price Swing3 Metal Stocks with Double-Digit UpsideMarch 11, 2024 6:05 AMView 3 Metal Stocks with Double-Digit UpsideAll Headlines Company DescriptionsCellectisNASDAQ:CLLSCellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.INmune BioNASDAQ:INMBINmune Bio, Inc., a clinical-stage immunology company, focuses on reprogramming the patient's innate immune system to treat cancer and neurodegenerative diseases. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma solid tumor and patients with high-risk myelodysplastic syndrome; INB03 to treat patients with cancers that express MUC4, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers; and XPro1595 for the treatment of Alzheimer's disease and Treatment Resistant Depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.Jounce TherapeuticsNASDAQ:JNCEJounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.Talaris TherapeuticsNASDAQ:TALSTalaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR001 for the patients with a severe form of scleroderma. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Wellesley, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.